NCT04202458View on ClinicalTrials.gov

Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK)

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 15, 2019

Primary Completion Date

August 20, 2021

Study Completion Date

November 22, 2021

Conditions
Ischemic Stroke
Interventions
DRUG

intra-arterial tenecteplase administration

Intra-arterial administration of 4mg tenecteplase is given after microcatheter navigation through the clot. Intra-arterial administration of tenecteplase (0.4 mg/min) continuously is given after the first attempt of thrombectomy device pass for 30 minutes, and then followed by DSA.

Trial Locations (1)

110840

General Hospital of Northern Theater Command, Shenyang

All Listed Sponsors
lead

General Hospital of Shenyang Military Region

OTHER

NCT04202458 - Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK) | Biotech Hunter | Biotech Hunter